Entelechon and Syntezza forge partnership for the Israeli market
The cooperation emphasizes the relevance of the Israeli market for European companies. Says Dr. Werner Deininger, Managing Director of Entelechon: "We are very proud to have found such an experienced partner in Syntezza. They will give us much more immediate access to our Israeli customers. Israel is a very exciting and dynamic environment for biotech developments."
Initially, gene synthesis and DNA analytics will be in the focus of the new partnership. However, looking farther into the future, both companies have even more ambitious plans: Entelechon as a provider of integrated solutions in synthetic biology aims at establishing contact with innovative research groups in Israel. Together with Syntezza, the company intends to start complex development projects in Israel, supported by currently developed solutions in the areas of protein engineering, metabolic modelling, and quantitative proteomics.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.